Expert opinion on drug metabolism & toxicology · 2025
Safety of concomitant use of oral anticoagulants and antidiabetic drugs: a systematic review of observational studies.
СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tassopoulou Paraskevi, Wang Wanqi, Meinert Fabian Maximilian, Riemer Thomas G, Douros Antonios
Аннотация
INTRODUCTION: We systematically reviewed observational studies assessing the safety of concomitant use of oral anticoagulants (OACs) and antidiabetic drugs (ADs).
METHODS: We systematically searched MEDLINE/PubMed and EMBASE up to 10/2024 for cohort, case-control, and case-only studies on concomitant use of OACs and ADs and the risk of adverse outcomes (hypoglycemia, bleeding). Risk of bias was assessed using the Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) tool.
RESULTS: We identified five cohort studies and two self-controlled case-series (n = 1,370,036). Concomitant use of sulfonylureas and warfarin was mostly associated with increased risks of hypoglycemia versus sulfonylurea use alone (five studies); results were heterogeneous when comparing concomitant use of sulfonylureas and warfarin versus concomitant use of sulfonylureas and DOACs (two studies) and concomitant use of non-sulfonylurea ADs and warfarin versus non-sulfonylurea AD use alone (two studies). Concomitant use of warfarin and sulfonylureas was not associated with the risk of bleeding versus warfarin use alone (one study). Via ROBINS-I, four studies were at moderate, one at serious, and two at critical risk of bias.
CONCLUSIONS: Given inconsistent findings and a non-negligible risk of bias, observational studies do not suggest major clinical hazards due to concomitant use of OACs and ADs. (PROSPERO registration: CRD42024505475).
METHODS: We systematically searched MEDLINE/PubMed and EMBASE up to 10/2024 for cohort, case-control, and case-only studies on concomitant use of OACs and ADs and the risk of adverse outcomes (hypoglycemia, bleeding). Risk of bias was assessed using the Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) tool.
RESULTS: We identified five cohort studies and two self-controlled case-series (n = 1,370,036). Concomitant use of sulfonylureas and warfarin was mostly associated with increased risks of hypoglycemia versus sulfonylurea use alone (five studies); results were heterogeneous when comparing concomitant use of sulfonylureas and warfarin versus concomitant use of sulfonylureas and DOACs (two studies) and concomitant use of non-sulfonylurea ADs and warfarin versus non-sulfonylurea AD use alone (two studies). Concomitant use of warfarin and sulfonylureas was not associated with the risk of bleeding versus warfarin use alone (one study). Via ROBINS-I, four studies were at moderate, one at serious, and two at critical risk of bias.
CONCLUSIONS: Given inconsistent findings and a non-negligible risk of bias, observational studies do not suggest major clinical hazards due to concomitant use of OACs and ADs. (PROSPERO registration: CRD42024505475).